Scholarlink

<p>CanAssist Breast (CAB), an immunohistochemistry (IHC) and artificial intelligence-based prognostic test, was developed on Hormone receptor-positive (HR +), HER2/neu-negative (HER2-) breast tumors from Indian patients and validated in retrospective global studies.&#xa0;CAB combines the expression of five protein biomarkers with three clinical parameters to segregate patients as low-risk (LR) or high-risk (HR) for distant recurrence.&#xa0;CAB has been in clinical use in South Asia, UAE, Turkey, and Iran for the last 8&#xa0;years on &gt; 7000 Early breast cancer (EBC) patients. Here we showcase for the first time, the real-world data on the usefulness of CAB to prognosticate across different clinicopathological parameters, histological types, and impact on treatment planning by analysing CAB usage in 5926 patients diagnosed from mid-2016 to 2024.&#xa0;Overall, CAB stratified 72% of patients as LR and 28% as HR for distant recurrence. Interestingly, CAB showed meaningful differences in HR proportions across different histological types; 19% and 29% in mucinous versus mixed mucinous, while 26% and 50% in papillary and micropapillary carcinomas, respectively.&#xa0;In the intermediate Ki67 group, CAB segregated 77% of patients as LR and 23% as HR. In conclusion, CAB is a first-of-its-kind prognostic test that serves as a cost-effective, suitable alternative to Western prognostic tests.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world data of CanAssist Breast- first immunohistochemistry and AI-based prognostic test

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月19日

查看全文
  • Tejal Deepak Durgekar,
  • Manvi Sunder,
  • Badada Ananthamurthy Savitha,
  • Payal Shrivastava,
  • Rahul Bhagat,
  • Naveen Krishnamoorthy,
  • Deepti K. Shivashimpi,
  • Manjiri Bakre

摘要

CanAssist Breast (CAB), an immunohistochemistry (IHC) and artificial intelligence-based prognostic test, was developed on Hormone receptor-positive (HR +), HER2/neu-negative (HER2-) breast tumors from Indian patients and validated in retrospective global studies. CAB combines the expression of five protein biomarkers with three clinical parameters to segregate patients as low-risk (LR) or high-risk (HR) for distant recurrence. CAB has been in clinical use in South Asia, UAE, Turkey, and Iran for the last 8 years on > 7000 Early breast cancer (EBC) patients. Here we showcase for the first time, the real-world data on the usefulness of CAB to prognosticate across different clinicopathological parameters, histological types, and impact on treatment planning by analysing CAB usage in 5926 patients diagnosed from mid-2016 to 2024. Overall, CAB stratified 72% of patients as LR and 28% as HR for distant recurrence. Interestingly, CAB showed meaningful differences in HR proportions across different histological types; 19% and 29% in mucinous versus mixed mucinous, while 26% and 50% in papillary and micropapillary carcinomas, respectively. In the intermediate Ki67 group, CAB segregated 77% of patients as LR and 23% as HR. In conclusion, CAB is a first-of-its-kind prognostic test that serves as a cost-effective, suitable alternative to Western prognostic tests.